Newswise — Alzheimer’s disease (AD) is one of the most important threats to seniors. So, unbiased pharmaceutical information is critical.
Therefore, “Payments from a drug’s maker should be revealed when an advocacy group recommends the FDA approve that firm’s Alzheimer’s drug.” says Leslie Norins, MD, PhD, CEO of Alzheimer’s Germ Quest, Inc.
Biogen recently tried, again, to secure FDA approval to market its anti-AD drug, aducanumab. But, the FDA’s own advisory committee of 11 experts delivered only one vote in favor of the move at its meeting on November 6.
The FDA also received a letter urging the drug’s approval from the Alzheimer’s Association, the main advocacy group against the disease. The three-page document, dated October 23, devoted just one sentence to the validity of the company’s application itself, saying only “..the publicly released…
